World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 26 April 2021
Main ID:  EUCTR2017-004295-55-LT
Date of registration: 01/02/2018
Prospective Registration: Yes
Primary sponsor: Celgene International II Sàrl
Public title: Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
Scientific title: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
Date of first enrolment: 12/03/2018
Target sample size: 1200
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004295-55
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Australia Austria Belarus Belgium Bosnia and Herzegovina Brazil Bulgaria
Canada China Croatia Czech Republic Czechia Denmark Finland France
Georgia Germany Greece Hong Kong Hungary Ireland Israel Italy
Japan Korea, Republic of Latvia Lithuania Mexico Moldova, Republic of Netherlands New Zealand
Norway Poland Portugal Puerto Rico Romania Russian Federation Saudi Arabia Serbia
Singapore Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan
Turkey Ukraine United Kingdom United States
Contacts
Name: Denesh Chitkara   
Address:  Rue du Pré-Jorat 14 2108 Couvet Switzerland
Telephone: +1908897 5751
Email: denesh.chitkara@bms.com
Affiliation:  Celgene International II Sàrl
Name: Denesh Chitkara   
Address:  Rue du Pré-Jorat 14 2108 Couvet Switzerland
Telephone: +1908897 5751
Email: denesh.chitkara@bms.com
Affiliation:  Celgene International II Sàrl
Key inclusion & exclusion criteria
Inclusion criteria:
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subjects who are not in clinical response and/or clinical remission after completing 12 weeks in the Induction Studies RPC01-3201 or RPC01-3202, subjects who experience relapse in the Maintenance Study RPC01-3203, subjects who complete the Maintenance Study RPC01-3203, subjects who complete at least 1 year of RPC01 2201.
2. Subject must provide written informed consent prior to any studyrelated procedures, and have the ability to comply with the Table of Events. For adolescents, a parent/legal guardian of the adolescent must sign the informed consent form. In addition, adolescent subjects must also agree to participate in the study by signing an assent form. A parent or guardian must be willing to supervise adherence to the protocol requirements. Adolescent subjects who reach the legal age of consent while participating in the study will be asked to sign an ICF themselves to acknowledge their willingness to continue in the study.
3. Female subjects of childbearing potential:
Note: For the purposes of this study, a female subject is considered to be
of childbearing potential if she is = 12 years of age or has reached menarche, whichever occurred first, and 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).
Must agree to practice a highly effective method of contraception throughout the study until completion of the 90-day Safety Follow-up Visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl Index of less than 1% per year when used consistently and correctly. Examples of acceptable methods of birth control in the study are the following:
• combined hormonal (containing oestrogen and progestogen) contraception, which may be oral, intravaginal, or transdermal
• progestogen-only hormonal contraception associated with inhibition of
ovulation, which may be oral, injectable, or implantable
• placement of an intrauterine device (IUD)
• placement of an intrauterine hormone-releasing system (IUS)
• bilateral tubal occlusion
• vasectomised partner
• complete sexual abstinence
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception.
Female condom and male condom should not be used together.
Counseling about pregnancy precautions and the potential risks of fetal exposure must be conducted for female subjects of childbearing potential. The Investigator will educate all females of child-bearing potential (FCBP) about the different options of contraceptive methods or abstinence at Day 1, as appropriate.
The subject will be re-educated every time her contraceptive measures/methods or ability to become pregnant changes. The female subject's chosen form of contraception must be effective by the time the female subject starts the study (for example, hormonal contraception should be initiated at least 28 days before Day 1).
Are the trial subjects under 18? yes
Number of subjects for this age range: 60
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1020
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subje

Exclusion criteria:
The presence of any of the following will exclude a subject from enrollment:
4.3.1. Exclusions Related to General Health:
1. Subject has any clinically relevant cardiovascular, hepatic, neurological, pulmonary [severe respiratory disease (pulmonary fibrosis or COPD)], ophthalmological, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the subject at risk by participating in the study
2. Subject is pregnant, lactating, or has a positive urine beta human chorionic gonadotropin (ß-hCG)
3. Subject has suspected or diagnosed intra-abdominal or perianal abscess that has not been appropriately treated
4.3.2. Exclusions Related to Medications:
4. Hypersensitivity to active ingredients or excipients of ozanimod
5. Subject has received any of the following therapies since the first dose of IP in the prior ozanimod study:
• treatment with a biologic agent as well as other treatments for CD such as etrasimod, filgotinib, upadacitinib
• treatment with an investigational agent other than ozanimod
• treatment with D-penicillamine, leflunomide, thalidomide, natalizumab, fingolimod or other S1P modulators
• treatment with lymphocyte-depleting therapies (eg, Campath®, anti-CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)
6. Subject is currently receiving or requires initiation of any of the following therapies:
• treatment with corticosteroids at a dose that exceeds the prednisone equivalent of >40 mg
• treatment with immunomodulatory agents (eg, AZA, 6-MP, or MTX)
• chronic non-steroidal anti-inflammatory drug (NSAID) use (note: occasional use of NSAIDs and acetaminophen [eg, headache, arthritis, myalgias, or menstrual cramps] and aspirin up to 325 mg/day is permitted)
• treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with 2 or more agents in combination known to prolong PR interval
• treatment with breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine, eltrombopag)
7. Subject is receiving treatment with any of the following drugs or interventions within the corresponding timeframe:
• CYP2C8 inhibitors (eg, gemfibrozil or clopidogrel) and inducers (eg, rifampicin)
• Monoamine oxidase inhibitors (eg, selegiline, phenelzine)
4.3.3. Exclusions Related to Laboratory Results:
8. Subject has any clinically significant abnormal ECG results which in the opinion of the Investigator may put the subject at risk.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Moderately to Severely Active Crohn’s Disease
MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders
Intervention(s)

Product Name: ozanimod
Product Code: RPC1063 (equivalent to ozanimod HCl)
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Ozanimod
Other descriptive name: OZANIMOD
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-

Product Name: ozanimod
Product Code: RPC1063 (equivalent to ozanimod HCl)
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Ozanimod
Other descriptive name: OZANIMOD
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-

Primary Outcome(s)
Timepoint(s) of evaluation of this end point: Due to the open-label nature of the study and the lack of a control group, all data will be summarized and no hypothesis testing will be performed. Each efficacy endpoint will be summarized and 95% confidence intervals around the estimates may also be presented. All efficacy data will be listed.
For all proportion-based efficacy endpoints, subjects with missing efficacy data will be considered non-responders.
For continuous efficacy endpoints, subjects with missing data will have their last post baseline value carried forward.
Observed-cases analyses will also be presented for all efficacy endpoints.
Secondary Objective: Not applicable
Main Objective: The objective of this study is to demonstrate the long-term safety and explore long-term efficacy of ozanimod for the treatment of subjects with moderately to severely active CD.
Primary end point(s): Key Efficacy Endpoints:
• Proportion of subjects with a CDAI score of < 150
• Proportion of subjects with a SES-CD decrease from baseline of = 50%
• Proportion of subjects with average daily abdominal pain score = 1 point, and average daily stool frequency = 3 points with abdominal pain and stool frequency no worse than baseline
• Proportion of subjects with CDAI reduction from baseline of = 100 points or CDAI score of < 150
• Proportion of subjects with absence of ulcers = 0.5 cm with no segment with any ulcerated surface = 10%
• Proportion of subjects with CDAI reduction from baseline of = 70 points
• Change from baseline in CDAI
• Proportion of subjects with CDAI reduction from baseline of = 100 points or CDAI score of < 150 and SES-CD decrease from baseline of = 50%
• Proportion of subjects with CDAI score of < 150 and SES-CD = 4 points and a SES CD decrease = 2 points
• Proportion of subjects with average daily abdominal pain score = 1 point and average daily stool frequency = 3 points and a stool frequency no worse than baseline and SES-CD = 4 points and a SES-CD decrease = 2 points
• Proportion of subjects with SES-CD = 4 points and a SES-CD decrease = 2 points
• Proportion of subjects with a CDAI score < 150 in subjects off corticosteroids
• Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of = 50%
Key Efficacy Endpoint specific to adolescents:
• Proportion of subjects with a pediatric CDAI (PCDAI) score of = 10 points
Exploratory Endpoints:
• Proportion of subjects with average daily abdominal pain score = 1 point, average daily stool frequency = 3 points with abdominal pain and stool frequency no worse than baseline, and SES-CD decrease from baseline = 50%
• Proportion of adolescent subjects with a decrease from baseline in PCDAI score = 15 points.
• Change from baseline in weight, body mass index (BMI), height, and height velocity z-scores (adolescents only)
• Change from baseline in PCDAI score and weighted PCDAI score (adolescents only)
• Efficacy in subjects (clinical response, clinical remission, and endoscopic improvement) as a function of baseline and change-from-baseline in biomarkers (eg, C-reactive protein, fecal calprotectin, highdensity lipoprotein, IgA, IL-7, collagen fragments)
• To assess impact of SARS-CoV-2 serologic status on subjects receiving ozanimod and CD and to support health authority requests.
- Exploratory measurements of SARS-CoV-2 serology (anti-SARS-CoV-2
total or IgG), from serum samples collected at W48 and annually thereafter.
Secondary Outcome(s)
Secondary end point(s): Not applicable
Timepoint(s) of evaluation of this end point: Not applicable
Secondary ID(s)
RPC01-3204
2017-004295-55-HU
Source(s) of Monetary Support
Celgene International II Sàrl
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 22/02/2018
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history